These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27794623)

  • 1. A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder.
    Thase M; Asami Y; Wajsbrot D; Dorries K; Boucher M; Pappadopulos E
    Curr Med Res Opin; 2017 Feb; 33(2):317-326. PubMed ID: 27794623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan.
    Higuchi T; Kamijima K; Nakagome K; Itamura R; Asami Y; Kuribayashi K; Imaeda T
    Int Clin Psychopharmacol; 2016 Jan; 31(1):8-19. PubMed ID: 26513202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT
    J Clin Psychiatry; 2007 Aug; 68(8):1246-56. PubMed ID: 17854250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
    McIntyre RS; Fayyad R; Mackell JA; Boucher M
    Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
    Schatzberg A; Roose S
    Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient outcomes with education, drug therapy, and support: a study of venlafaxine ER-treated outpatients with major depressive disorder.
    Lobello K; Reddy S; Musgnung J; Pedersen R; Ninan PT
    Psychopharmacol Bull; 2010; 43(2):28-44. PubMed ID: 21052041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis.
    Kato M; Asami Y; Wajsbrot DB; Wang X; Boucher M; Prieto R; Pappadopulos E
    J Psychiatr Res; 2020 Oct; 129():160-167. PubMed ID: 32912597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.
    Katz IR; Reynolds CF; Alexopoulos GS; Hackett D
    J Am Geriatr Soc; 2002 Jan; 50(1):18-25. PubMed ID: 12028242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Response and remission in depressive patients with anxiety symptoms treated with venlafaxine extended release in primary care].
    Roca Benassar M; Baca Baldomero E
    Actas Esp Psiquiatr; 2006; 34(3):162-8. PubMed ID: 16736389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
    Rudolph RL; Feiger AD
    J Affect Disord; 1999 Dec; 56(2-3):171-81. PubMed ID: 10701474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors impacting the efficacy of venlafaxine extended release 75-225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan.
    Watanabe Y; Asami Y; Hirano Y; Kuribayashi K; Itamura R; Imaeda T
    Neuropsychiatr Dis Treat; 2018; 14():1261-1272. PubMed ID: 29844674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
    Silverstone PH; Ravindran A
    J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.